Tylenol Crisis History: 1982 Poisonings to Autism Claims
The Tylenol crisis is three separate events. In 1982, cyanide-laced capsules killed seven people near Chicago and Johnson & Johnson recalled about 31 million bottles, the Philadelphia Inquirer reported. In 2010, McNeil recalled more than 136 million bottles of children's liquid medicines, the FDA told Congress. In 2025, officials alleged a link between acetaminophen in pregnancy and autism, which the FDA says is not established as causal.
What happened in the 1982 Tylenol poisonings?
The 1982 Tylenol poisonings killed seven people in the Chicago area after someone replaced the contents of Extra Strength Tylenol capsules with cyanide. The Philadelphia Inquirer reported in 2012 that the seven deaths came over three days beginning September 29, 1982. Packaging Gateway reports that the poisoned bottles were deliberately placed on store shelves, so the tampering happened after the product left the factory.
Johnson & Johnson, led by chief executive James E. Burke, pulled Tylenol capsules from shelves nationwide. Steve Dnistrian, who worked with Burke and later became Johnson & Johnson's vice president for communications, told the Inquirer in 2012 that the recall covered about 31 million bottles and cost the company more than $100 million. EBSCO's research summary puts the cost at $240 million and reports that Extra Strength Tylenol returned to stores in January 1983 in tamper-resistant packaging. The company's full response is covered in the 1982 Tylenol crisis masterclass.
The poisoner was never identified. Packaging Gateway notes that James William Lewis, who sent the company a letter demanding $1 million, was arrested for extortion but was never proven to be the poisoner.
Why did the 2010 children's Tylenol recall hurt Johnson & Johnson?
The 2010 recall hurt Johnson & Johnson because it covered more than 136 million bottles of infants' and children's liquid medicines and exposed manufacturing failures at McNeil's plant in Fort Washington, Pennsylvania. The Philadelphia Inquirer reported in May 2010 that Joshua Sharfstein, then the FDA's principal deputy commissioner, told Congress the recall was the largest ever for children's medicines. Sharfstein tied it to years of concerns about the plant's manufacturing quality.
McNeil announced the recall on April 30, 2010, and said it was not based on adverse medical events. McNeil's notice listed infants' and children's Tylenol, Zyrtec and Benadryl liquids, and the Inquirer reported that Motrin liquids were also covered. The U.S. Attorney's Office for the Eastern District of Pennsylvania later said FDA inspectors found 30 batches of affected liquid medicines and that McNeil lacked a corrective-action plan for metal particles reported by consumers.
The recall also drew scrutiny of how the company communicated. The Inquirer reported in 2012 that congressional staff and the FDA had looked into a so-called phantom recall, in which Johnson & Johnson hired a contractor in 2009 to buy McNeil-made Motrin off shelves without publicity. In March 2011 the FDA entered a consent decree that barred the Fort Washington plant from operating until it met quality standards, and Johnson & Johnson said it was investing $100 million in upgrades. In 2015, McNeil-PPC pleaded guilty to a criminal charge over adulterated infants' and children's medicines and agreed to a $20 million fine and a $5 million forfeiture, according to the U.S. Attorney's Office.
The 2025 Tylenol dispute is a disagreement over whether acetaminophen taken during pregnancy is associated with autism and ADHD, and no causal link has been established. On September 22, 2025, the Department of Health and Human Services announced that the FDA would send physicians a notice and begin a process to change acetaminophen's safety label. HHS said in the same announcement that the FDA recognizes studies showing no association and that untreated fever in pregnancy carries risks. At the White House event, President Donald Trump told pregnant women, "Don't take Tylenol," according to CNN and ABC News.
Medical groups disagreed. Steven Fleischman, president of the American College of Obstetricians and Gynecologists, said in a Monday statement reported by The Hill that no reputable study has shown that acetaminophen in any trimester of pregnancy causes neurodevelopmental disorders. ABC News reported that major medical groups continue to recommend acetaminophen as the safest painkiller during pregnancy.
In late October 2025, Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue, the company that has sold Tylenol since 2023, under the Texas Deceptive Trade Practices Act. CNN reported that the suit alleges Tylenol was deceptively marketed to pregnant women. Kenvue said in a statement that it would defend itself against claims it called baseless, and Johnson & Johnson said Kenvue holds the rights and liabilities for Tylenol. Kenvue's quarterly SEC filing for the period ended June 28, 2026 reports that some claims were dismissed in November 2025 and that a notice of appeal was filed in December 2025.
Ownership of Tylenol is also changing. Kimberly-Clark announced on November 3, 2025 that it would acquire Kenvue, and shareholders of both companies approved the deal on January 29, 2026, according to the companies' joint press release filed with the SEC. Kimberly-Clark's quarterly filing for the period ended June 30, 2026 says completion was expected in the second half of 2026. TipRanks reported that Kimberly-Clark said on October 13, 2026 that it expected to close the acquisition later in the fourth quarter of 2026.
This article reports the dispute and is not medical advice. Anyone who is pregnant, or who gives acetaminophen to a child, should ask a doctor or pharmacist.
How do the three Tylenol crises compare?
The three Tylenol crises differ in cause, scale and in who controlled the story, as the table below shows. The broader company history, including the Kenvue separation, is in Johnson & Johnson's PR history.
Crisis
Trigger
Scale
How the story reached the public
1982 poisonings
Capsules tampered with after leaving the factory
Seven deaths, about 31 million bottles recalled
Johnson & Johnson announced a nationwide capsule recall through its chief executive
2010 recalls
Manufacturing failures at McNeil's Fort Washington plant
More than 136 million bottles of liquid medicines
McNeil announced the recall, then regulators, Congress and the press drove later coverage, including the Motrin phantom recall
2025 autism dispute
Government statements and a Texas lawsuit about acetaminophen in pregnancy
No recall, no established causal link
Federal officials and the Texas attorney general set the terms, and Kenvue responded with statements and court filings
What do the Tylenol crises teach about crisis communications?
The Tylenol crises show that the response a company needs depends on whether the claim concerns a defect, a label or the science. In 1982 the defect was a criminal act, and the company's own decision to recall every capsule set the story. In 2010 the defect was internal, and parts of the story came out through regulators and Congress instead of through the company.
The 2025 dispute is different because no manufacturing defect is alleged. The claim concerns an ingredient and the evidence is contested, so a recall does not answer it. Kenvue's public position has been to cite the medical community and defend the drug's safety, which puts the burden on an evidence argument, not a product withdrawal.
A communications team facing a regulator's claim should first decide which of the three it is facing, because each calls for a different action: a recall, a label negotiation, or a public case built on published evidence. For a recall announced and explained in the same year as the McNeil recalls, see the Nissan 2010 recall breakdown. The through-line from 1982 to 2025 is who tells the story first and whether the facts hold up.
Philadelphia Inquirer, "Executive steered J&J through Tylenol killings," October 2, 2012
Packaging Gateway, "How the Tylenol Murders forever changed product packaging," August 2, 2023
EBSCO Research Starters, "Seven People Die After Taking Cyanide-Laced Tylenol"
Philadelphia Inquirer, "Johnson & Johnson shakes up Fort Washington plant," May 28, 2010
Philadelphia Inquirer, "Johnson & Johnson, Montco plant sued in boy's death," January 5, 2012
Philadelphia Inquirer, "FDA cracks down on J&J sites linked to recalls," March 11, 2011
McNeil Consumer Healthcare recall notice, May 1, 2010 (reproduced from FDA.gov by ENEWSPF)
U.S. Attorney's Office, Eastern District of Pennsylvania, "McNeil-PPC, Inc. pleads guilty in connection with adulterated infants' and children's liquid drugs"
U.S. Department of Health and Human Services, "President Trump, Secretary Kennedy Announce Bold Actions to Tackle Autism Epidemic," September 22, 2025
CNN, "Trump links autism to acetaminophen use during pregnancy, despite decades of evidence it's safe," September 22, 2025
ABC News, "Trump administration recommends pregnant women limit Tylenol, contradicting medical guidance," September 2025
The Hill, "FDA initiates label change on Tylenol to warn of autism," September 23, 2025
CNN, "Texas attorney general sues Tylenol makers, claiming links to autism," October 28, 2025
ABC News, "Texas AG sues makers of Tylenol, claiming they hid alleged links to autism," October 28, 2025
HealthDay via Infectious Disease Advisor, "Texas Sues Tylenol Over Alleged Autism Link," October 31, 2025
Kenvue Inc., Form 10-Q for the period ended June 28, 2026, SEC EDGAR
Kimberly-Clark, "Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader," November 3, 2025
Kimberly-Clark and Kenvue, joint press release on shareholder approvals, January 29, 2026 (SEC filing)
Kimberly-Clark Corporation, Form 10-Q for the period ended June 30, 2026, SEC EDGAR
TipRanks, "Kimberly-Clark Advances Kenvue Notes Exchange and Acquisition," October 2026
How this was made: this article was drafted with AI assistance and checked against the sources listed above.
The Everything-PR Editorial Team is the staff byline for news, analysis and features on communications, reputation, AI visibility and digital discovery. Everything-PR has published since 2009. AI tools assist with research and drafting, and every article is reviewed by a human editor before publication. Coverage follows the Editorial Policy, and substantive corrections are noted on the article under the Corrections Policy.
